RMT Holding Group

RMT Holding Group is a Japanese biotechnology holding company specializing in the development and commercialization of regenerative medicine and cell therapies. The group focuses on utilizing mesenchymal stem cells (MSCs) to treat a variety of unmet medical needs, including orthopedic disorders and immune-related conditions. Through its subsidiaries, RMT Holding Group manages the entire lifecycle of cell products, from R&D and clinical trials to specialized manufacturing in GMP-compliant facilities. Their lead candidate, RMT-01, is being evaluated for the treatment of knee osteoarthritis. The company aims to provide innovative, high-quality regenerative solutions to the global healthcare market.